Feedback (FDBK) – Issue of Equity

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce the completion of a placing of 27,272,727 new ordinary shares of 0.25p each in the Company at a price of 2.75 pence per Placing Share to raise a total of £750,000 (before expenses). The Placing is subject to admission of the Placing […]

Feedback Plc (FDBK) – Brand CEO Alan Green discusses developments on the Vox Markets podcast

Originally published on Wednesday April 5th 2017, Brand CEO Alan Green discusses the emergence of TexRAD texture analysis software as a benchmark medical imaging tool, and the Cadran image archiving system, developed by Cambridge Computed Imaging, in use at Papworth hospital. Both are systems are owned by Feedback (FDBK). Together with Justin Waite on the Vox Markets podcast, Alan discusses the […]

Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD

Correlation of CT Derived Texture Features with Mutational Status of Clear Cell Renal Carcinoma using TexRAD – Preliminary Findings Presentation at Society of Abdominal Radiology (SAR) Annual Conference Sahand Sohrabi and Raghunandan Vikram – Diagnostic Imaging, MD Anderson Cancer Center, Houston, Texas, USA Purpose: To investigate role of CT Texture analysis (CTTA) and mutational status […]

Feedback Plc (FDBK) – Letter of Intent signed and trading update

Letter of Intent signed with leading global medical imaging company and trading update Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to update shareholders on current developments. The Group’s efforts are being concentrated on obtaining the CE mark for TexRAD Lung by the target date of May 2017. The CE mark will […]

TexRAD presentation at European Congress of Radiology (ECR) – Feedback (FDBK)

Today’s presentation by Dr. Alessandro Scavuzzo from Brescia University Hospital at the European Congress of Radiology further demonstrates the utility of TexRAD on MRI in a new application in cardiovascular disorders (e.g. dilated cardiomyopathy) specifically highlighting the ability of TexRAD MR texture analysis as a non-invasive imaging biomarker showing association with the clinical score and patient […]